[Form 4] iBio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

iBio, Inc. (IBIO) reported that one of its directors received a new stock option grant. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share.

These options vest pro rata on a monthly basis over twelve months starting from the grant date, meaning the director earns a portion of the options each month during the first year. The options have an expiration date of 11/19/2035, giving a long period in which they may be exercised, subject to the vesting schedule and any applicable company or regulatory requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parada Antonio Bernardino Guimaraes

(Last) (First) (Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY, ROAD, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$1	11/20/2025		A		13,500(1)		(1)	11/19/2035	Common Stock	13,500	$0	13,500	D

Explanation of Responses:

1. These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

	/s/ Marc Banjak, Attorney-in-fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did iBio (IBIO) disclose in this Form 4 filing?

iBio disclosed that a director received a stock option grant for 13,500 shares of common stock at an exercise price of $1.00 per share on 11/20/2025.

Who is the reporting person in this iBio (IBIO) Form 4?

The reporting person is identified as a director of iBio, Inc., as indicated by the checked box for the relationship to the issuer.

What are the key terms of the iBio (IBIO) director stock options?

The director received stock options for 13,500 shares of common stock at $1.00 per share, granted on 11/20/2025, expiring on 11/19/2035.

How do the iBio (IBIO) director stock options vest?

The options vest pro rata on a monthly basis over twelve months starting from the grant date, so the director earns a portion each month in the first year.

Does this Form 4 show derivative or non-derivative securities for iBio (IBIO)?

The filing reports derivative securities, specifically a stock option (right to buy) for 13,500 shares of iBio common stock.

What is the ownership form of the reported iBio (IBIO) stock options?

The Form 4 indicates the ownership form is Direct (D) for the 13,500 stock options held by the director.